文献速递糖尿病

高剂量口服胰岛素对1型糖尿病1期儿童的影响:Fr1da胰岛素干预随机对照试验

Effect of High-Dose Oral Insulin in Children With Stage 1 Type 1 Diabetes: The Fr1da Insulin Intervention Randomized Controlled Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

该2期随机安慰剂对照双盲试验纳入220例1型糖尿病1期儿童,每日口服高剂量胰岛素(前3个月7.5 mg/天,后9个月67.5 mg/天)或安慰剂12个月。主要结局为从基线至血糖异常或临床糖尿病的时间及12个月内对胰岛素的免疫反应增强。结果显示口服胰岛素未改变疾病进展或免疫反应,且耐受性良好。

要点

  • 高剂量口服胰岛素未延缓1型糖尿病1期儿童向血糖异常或临床糖尿病的进展。
  • 口服胰岛素组与安慰剂组的5年进展率均为40%(95%CI 30-51%)。
  • 口服胰岛素未增强对胰岛素的免疫反应,且耐受性良好。

核心结论

  • 在1型糖尿病1期儿童中,为期1年的高剂量口服胰岛素治疗未改变向血糖异常或糖尿病的进展,也未改变对胰岛素的免疫反应。

研究设计与样本

  • 2期随机安慰剂对照双盲试验,纳入220例1型糖尿病1期儿童,随机接受口服胰岛素(n=110)或安慰剂(n=110)治疗12个月。

主要发现

  • 共179例完成试验;87例出现血糖异常或糖尿病(口服胰岛素组46例,安慰剂组41例),风险比1.07(95%CI 0.66-1.73;P=0.74)。
  • 两组的5年进展率均为40%(95%CI 30-51%)。
  • 对胰岛素的免疫反应增强在口服胰岛素组44例中观察到11例(25%),安慰剂组42例中观察到13例(31%)(P=0.63)。
  • 口服胰岛素耐受性良好,未发生显著的研究相关不良事件。
  • 发现与INS rs689基因型存在轻微的治疗交互作用(P=0.03)。

关键数值与推荐

  • 口服胰岛素剂量:前3个月7.5 mg/天,后9个月67.5 mg/天,共12个月。
  • 主要结局:从基线至血糖异常或临床糖尿病的时间;12个月内对胰岛素的免疫反应增强(在前90例参与者中评估)。

临床怎么用

  • 对于1型糖尿病1期儿童,高剂量口服胰岛素不推荐用于延缓疾病进展。

局限性

  • 免疫反应评估仅在前90例参与者中进行。
  • 试验未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oral administration of an antigen can induce immunological tolerance. Insulin is an autoantigen in childhood type 1 diabetes (T1D). We tested the effect of treatment with high-dose oral insulin on disease progression and immune response to insulin in children with stage 1 T1D. RESEARCH DESIGN AND METHODS: We conducted a phase 2 randomized placebo-controlled double-blind trial in children with stage 1 T1D who received daily oral insulin (7.5 mg/day for 3 months and 67.5 mg/day for 9 months; n = 110) or placebo (n = 110) for 12 months. The coprimary outcomes were 1) time from baseline to dysglycemia or clinical diabetes and 2) increased immune response to insulin within 12 months of treatment (assessed in the first 90 participants). RESULTS: Of 220 participants (112 girls; median age 4.8 years; interquartile range 3.6, 6.2), 179 completed the trial. Dysglycemia or diabetes developed in 87 participants (46 receiving oral insulin and 41 receiving placebo; hazard ratio 1.07; 95% CI 0.66-1.73; P = 0.74). The 5-year progression rate was 40% (95% CI 30-51%) in each group. A modest treatment interaction was found with the INS rs689 genotype (P = 0.03). Increased immune response to insulin was observed in 11 (25%) of 44 participants in the oral insulin group and 13 (31%) of 42 in the placebo group (P = 0.63). Oral insulin was well tolerated. No significant study-related adverse events occurred. CONCLUSIONS: In children with stage 1 T1D, 1 year of high-dose oral insulin did not alter progression to dysglycemia or diabetes or immune response to insulin.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ziegler AG, Albeer A, Arnolds S, et al. Effect of High-Dose Oral Insulin in Children With Stage 1 Type 1 Diabetes: The Fr1da Insulin Intervention Randomized Controlled Trial. Diabetes Care. 2026. PMID: 41563349. doi:10.2337/dc25-2818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。